Bank of New York Mellon
RCPI

Bank of New York Mellon’s ROCK CREEK PHARMACEUTICALS INC COM STK (DE) RCPI Stock Holding History

Bank of New York Mellon’s Portfolio RCPI Stock Details RCPI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-5,624
Closed -$14K – 4408
2015
Q1 		$14K Sell
5,624
-832
-13% -$3.27K ﹤0.01% 4206
2014
Q4 		$29K Hold
6,456
– – ﹤0.01% 4190
2014
Q3 		$45K Hold
6,456
– – ﹤0.01% 4152
2014
Q2 		$95K Buy
+6,456
New +$112K ﹤0.01% 4001

Other funds holding RCPI

Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
TCM
Tenor Capital Management New York $6.49B AUM 3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 19.31% 1-Year Est. Return
TC
Talkot Capital Sausalito, California $73.7M AUM 8.5% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Bank of New York Mellon's RCPI Position: Q2 2015 in Review

Bank of New York Mellon sold out of ROCK CREEK PHARMACEUTICALS INC COM STK (DE) (RCPI) in Q2 2015, closing a stake of 5,624 shares — an estimated $14K sold.

Bank of New York Mellon first reported a position in RCPI in Q2 2014 and held it in 4 quarters. The position peaked at $95K in Q2 2014. 36 funds tracked by Wall St. Rank hold RCPI as of Q2 2015.

  • Bank of New York Mellon reported no remaining ROCK CREEK PHARMACEUTICALS INC COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • Bank of New York Mellon sold 5,624 ROCK CREEK PHARMACEUTICALS INC COM STK (DE) shares in Q2 2015, an estimated $14K.
  • Bank of New York Mellon first reported a position in ROCK CREEK PHARMACEUTICALS INC COM STK (DE) in Q2 2014 and held it in 4 quarters.
  • Bank of New York Mellon's ROCK CREEK PHARMACEUTICALS INC COM STK (DE) position peaked at $95K in Q2 2014.
  • 36 funds tracked by Wall St. Rank held ROCK CREEK PHARMACEUTICALS INC COM STK (DE) as of Q2 2015.

Based on Bank of New York Mellon's 13F filing for Q2 2015, filed 6 Aug 2015.